Resomelagon progresses in RA, viral infections

SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency due to viral infections (n=96). Together, these developments reinforce SynAct’s dual clinical strategy for resomelagon in both chronic inflammatory disease and the acute hospital setting. While recruitment progress in the ADVANCE trial de-risks trial execution, database closure and analysis timelines imply top-line ADVANCE data will likely move from our previously anticipated Q126 window into Q226. We expect top-line readouts from the ADVANCE trial to remain the key catalyst for partnering discussions and valuation inflection. We wi...